GlassScriptPhysician profile
Calvin A Bell
NPI 1821062258
$609.95
in general payments reported to CMS, 2019-2025
11 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.86 · 2020: $42.53 · 2021: $53.68 · 2022: $102 · 2023: $71.11 · 2024: $127 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $337.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $229.83 | 2019-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.15 | 2022-2024 | Jardiance |
| Novo Nordisk INC | $83.58 | 2024-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $49.98 | 2019-2022 | |
| Medtronic, INC. | $46.91 | 2024-2025 | Venaseal, Hawkone |
| Merck Sharp & Dohme LLC | $28.89 | 2025 | Verquvo |
| Glaxosmithkline, LLC. | $25.49 | 2025 | |
| Novartis Pharmaceuticals Corporation | $15.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.17 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.55 | 2019 | |
| Daiichi Sankyo INC. | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.